Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist

详细信息    查看全文

• 作者：Christina Charles-Schoeman ; MD ; MS^a ; ^{CCharles@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author} ; Miguel A. Gonzalez-Gay ; MD ; PhD^b ; Irina Kaplan ; PhD^c ; Mary Boy ; VMD^c ; Jamie Geier ; PhD^d ; Zhen Luo ; PhD^e ; Andrea Zuckerman ; MD^c ; Richard Riese ; MD ; PhD^c
• 关键词：Apo ; apolipoprotein ; BID ; twice daily ; CV ; cardiovascular ; CVD ; cardiovascular disease ; CE ; cholesterol ester ; CETP ; cholesterol ester transfer protein ; CRP ; C-reactive protein ; DAS28 ; Disease Activity Score with 28 joint-count ; DMARD ; disease-modifying antirheumatic drug ; EULAR ; European League Against Rheumatism ; FC ; free cholesterol ; FCR ; fractional catabolic rate ; HDL ; high-density lipoprotein ; HDL-C ; high-density lipoprotein cholesterol ; JAK ; Janus kinase ; LCAT ; lecithin&ndash ; cholesterol a
• 刊名：Seminars in Arthritis and Rheumatism
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：46
• 期：1
• 页码：71-80
• 全文大小：1198 K

文摘

Cardiovascular (CV) morbidity and mortality are increased in patients with active, untreated rheumatoid arthritis (RA), despite lower levels of total and low-density lipoprotein cholesterol reported in individuals with active RA compared with those without RA. Alterations in non-traditional lipid assessments, such as high-density lipoprotein (HDL) function and HDL-associated proteins, have been described in patients with active RA, including elevated HDL-associated serum amyloid A and decreased paraoxonase-1 activity. We review changes in both traditional lipoprotein concentrations and non-traditional lipoprotein assessments in multiple studies of treatment with disease-modifying antirheumatic drugs (DMARDs), including non-biologic and biologic DMARDs and tofacitinib. In addition, data from a recently published clinical trial with tofacitinib that describe a potential mechanism for suppression of cholesterol levels in active RA patients are reviewed. Finally, CV event data from various studies of DMARDs are presented, and the current management of RA patients with regard to the CV risk is reviewed.